Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series | Zendy

Koba Hayato | Zendy; Yoneda Taro | Zendy; Kaneda Tomoya | Zendy; Ueda Tsukasa | Zendy; Kimura Hideharu | Zendy; Kasahara Kazuo | Zendy

Open Access

Severe coronavirus disease 2019 (COVID‐19) pneumonia patients treated successfully with a combination of lopinavir/ritonavir plus favipiravir: Case series

Author(s) -

Koba Hayato,

Yoneda Taro,

Kaneda Tomoya,

Ueda Tsukasa,

Kimura Hideharu,

Kasahara Kazuo

Publication year - 2020

Publication title -

clinical case reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.21

H-Index - 9

ISSN - 2050-0904

DOI - 10.1002/ccr3.3358

Subject(s) - lopinavir , medicine , favipiravir , lopinavir/ritonavir , ritonavir , covid-19 , pneumonia , virology , coronavirus , betacoronavirus , pandemic , intensive care medicine , disease , viral load , virus , antiretroviral therapy , infectious disease (medical specialty) , outbreak

Key Clinical Message The combination therapy of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID‐19. Serum ferritin levels and lymphocytopenia are promising markers for disease severity and disease progression that are commonly available in general clinical practice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research